CRAC entered a Business Combination Agreement with Carvix and Merger Sub on March 30, 2026: Domestication to Delaware then Merger Sub into Carvix, Carvix surviving as wholly owned sub. Carvix holders get 50,000,001 CRAC shares at Effective Time plus contingent earnout up to 50,000,100 shares over four Payment Years; Sponsor may earn up to 3,000,000 separate earnout shares. Closing needs SPAC stockholder approval, Carvix written consent, effective S-4, Nasdaq listing, HSR if required, NTA/penny-stock condition, and Minimum Cash Amount after redemptions and expenses. Outside Date is September 30, 2026; termination paths include failed vote, breach, missing audited financials, or no close by Outside Date. DA firms close-path versus prior silence; cash outcome still turns on redemptions and Minimum Cash. Rights stated as 0.20 of one Class A share at business combination consummation.

Conversion 1/5